National Research and Innovation Lymphoedema Specialist, Lymphoedema Network Wales, Cimla Health and Social Care Centre, Cimla, Neath.
National Clinical Lead/Associate Director for Lymphoedema in Wales, Lymphoedema Network Wales, Cimla Health and Social Care Centre, Cimla, Neath.
Br J Nurs. 2021 May 27;30(10):592-598. doi: 10.12968/bjon.2021.30.10.592.
To ensure lymphoedema patients in Wales receive the right care, at the right time, by the right person, patient-reported outcome measures (PROMs) were routinely completed within the All-Wales lymphoedema assessment documentation. This evaluation describes the development of the Lymphoedema Patient Reported Outcome Measure (LYMPROM), which is a tool developed by Lymphoedema Network Wales clinicians and key stakeholders. The tool was explored for face, form and content validity during 3 months in 2019; 128 anonymised completions of LYMPROM were reviewed to establish feasibility, acceptability and internal validity using Cronbach's alpha. LYMPROM was feasible and acceptability was high. Face and content validity were reported (i-CVI [item content validity index] range=0.43 - 1; s-CVI/Ave=0.94) and internal consistency was excellent (0.958). LYMPROM was easily integrated within lymphoedema services in Wales, promoting patient-led care and supporting value-based health care. Further evaluations of reliability and validity of LYMPROM are proceeding along with digital integration.
为确保威尔士的淋巴水肿患者能在适当的时间由合适的人员接受适当的护理，在全威尔士的淋巴水肿评估文件中，患者报告结局测量（PROMs）被常规完成。本评估描述了由威尔士淋巴水肿网络临床医生和主要利益相关者开发的淋巴水肿患者报告结局测量（LYMPROM）工具的开发过程。该工具于 2019 年的 3 个月内进行了表面、形式和内容有效性的探索；使用 Cronbach's alpha 对 128 份匿名的 LYMPROM 完成情况进行了审查，以确定其可行性、可接受性和内部有效性。LYMPROM 具有可行性且可接受性高。报告了表面和内容有效性（i-CVI [项目内容有效性指数]范围为 0.43-1；s-CVI/Ave=0.94），内部一致性极好（0.958）。LYMPROM 很容易在威尔士的淋巴水肿服务中得到整合，促进了以患者为中心的护理，并支持基于价值的医疗保健。LYMPROM 的可靠性和有效性的进一步评估正在进行，并进行数字化整合。
